Aptargroup Inc
NYSE:ATR

Watchlist Manager
Aptargroup Inc Logo
Aptargroup Inc
NYSE:ATR
Watchlist
Price: 121.91 USD -0.09% Market Closed
Market Cap: 8B USD

Aptargroup Inc
Investor Relations

AptarGroup Inc., a name that might not immediately resonate with the average consumer, plays a pivotal role in the transformation of everyday experiences across the globe. Operating at the forefront of packaging solutions, AptarGroup ingeniously bridges the worlds of beauty, pharmaceuticals, food, and beverage through its innovative dispensing systems. The company specializes in designing and manufacturing a wide array of delivery solutions, including pumps, closures, aerosol valves, and spray devices. These products, often hidden within the framework of beloved consumer brands, enhance usability, preserve product integrity, and elevate user satisfaction. AptarGroup’s commitment to innovation is fueled by substantial investments in research and development, positioning the company as a strategic partner to its clients, who rely on Aptar’s expertise to create intuitive and reliable packaging.

In the business landscape, AptarGroup thrives by embedding itself deeply into the supply chains of some of the world's most iconic brands. By understanding the nuanced needs of different industries, the company tailors its solutions to meet diverse market demands, leading to long-standing collaborations and contracts. AptarGroup's business model focuses on both broadening its market reach and deepening its expertise in key areas, allowing for diversification and reduced dependency on any single market sector. This strategic versatility not only enhances their competitive edge but also fortifies their revenue streams. Whether it's the precision required in pharmaceutical packaging or the aesthetic demands of cosmetic products, AptarGroup’s prowess lies in its ability to harmonize functionality with form, ensuring consumer satisfaction while driving sustainable growth in the packaging industry.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Oct 31, 2025
AI Summary
Q3 2025

EPS Beat: Adjusted EPS for the quarter was $1.62, up 4% year-over-year and above consensus.

Pharma Growth: Pharma core sales rose 2%, with strong growth in injectables (18%) and active material science (3%), but emergency medicine and consumer healthcare faced near-term headwinds.

Emergency Medicine Outlook: Emergency medicine (including Narcan) will be a headwind into 2026, with revenues expected to decline approximately 35% next year due to customer inventory normalization.

Segment Margins: Pharma margin improved 120 bps to 37.2%; Beauty margin fell 120 bps to 12.1%; Closures margin declined 110 bps to 16.1%.

Shareholder Returns: Share repurchases reached $190 million (1.3 million shares), the highest in a decade; dividend increased nearly 7% to $0.48 per share.

Q4 Guidance: Q4 adjusted EPS expected between $1.20 and $1.28; positive core sales growth anticipated in Beauty and continued closure volume growth.

M&A Activity: Announced acquisition of Soma Plus in Brazil to expand oral dosing pharma packaging footprint.

Key Financials
Adjusted Earnings Per Share
$1.62
Beauty Adjusted EBITDA Margin
12.1%
Pharma Adjusted EBITDA Margin
37.2%
Closures Adjusted EBITDA Margin
16.1%
SG&A as % of Sales
15.5%
Consolidated Adjusted EBITDA Margin
23.2%
Adjusted EBITDA (YTD)
$624 million
Adjusted EBITDA Margin (YTD)
22.2%
Reported Earnings Per Share (YTD)
$4.75
Adjusted Earnings Per Share (YTD)
$4.48
Free Cash Flow (YTD)
$206 million
Cash and Short-term Investments
$265 million
Net Debt
$936 million
Leverage Ratio
1.22
Share Repurchases (YTD)
$190 million
Shares Repurchased (YTD)
1.3 million shares
Dividend per Share (Quarterly)
$0.48
Available Share Repurchase Authorization
$270 million
Effective Tax Rate (Q3)
17.1%
Adjusted Effective Tax Rate (Q3)
20.8%
Depreciation & Amortization (Q4 Guidance)
$75–80 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Stephan B. Tanda
President, CEO & Executive Director
No Bio Available
Mr. Robert W. Kuhn
Executive VP & CFO
No Bio Available
Mr. Gael Touya
President of Aptar Pharma
No Bio Available
Mr. Marc Prieur
President of Aptar Beauty
No Bio Available
Mr. Daniel Richard Ackerman
Chief Accounting Officer
No Bio Available
Ms. Mary Skafidas
Senior Vice President of Investor Relations & Communications
No Bio Available
Ms. Shiela Pallerne Vinczeller
Chief Human Resources Officer
No Bio Available
Mr. Hedi Tlili
President of Aptar Closures
No Bio Available

Contacts

Address
ILLINOIS
Crystal Lake
265 Exchange Dr Ste 100
Contacts
+18154770424.0
www.aptar.com